IDEAYA Biosciences, Inc.

Historical 13F Holders

Symbol
IDYA
CUSIP
45166A102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 45166A102 since 12/18/2024, newest first.

Filer % of Class Filed
Baker Bros. Advisors LP 13G
5.2% 8/14/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Janus Henderson Group PLC 13G/A Amendment 6 8.3% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 1 0% 3/27/2026
Event 3/13/2026
Point72 Asset Management, L.P. 13G/A Amendment 1
2.1% 2/17/2026
Event 12/31/2025
Capital Research Global Investors 13G/A Amendment 1 6.0% 2/12/2026
Event 12/31/2025
Federated Hermes, Inc. 13G/A Amendment 3
3.9% 1/8/2026
Event 12/31/2025
Janus Henderson Group PLC 13G/A Amendment 5 7.3% 11/14/2025
Event 9/30/2025
Janus Henderson Group PLC 13G/A Amendment 4 6.9% 8/14/2025
Event 6/30/2025
Capital Research Global Investors 13G 7.5% 8/13/2025
Event 6/30/2025
Point72 Asset Management, L.P. 13G
5.0% 6/9/2025
Event 6/6/2025
Janus Henderson Group PLC 13G/A Amendment 3 7.3% 5/14/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 4 8.1% 4/17/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 2 6.8% 2/14/2025
Event 12/31/2024
BlackRock, Inc. 13G/A Amendment 3 9.7% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 7 154 k $5.90 M
2026 Q2 297 106 M $3.90 B
2026 Q1 271 94.7 M $3.16 B
2025 Q4 260 95.9 M $3.32 B
2025 Q3 233 94.3 M $2.56 B
2025 Q2 213 97.3 M $2.05 B
2025 Q1 215 93.9 M $1.54 B
2024 Q4 211 92.0 M $2.36 B
2024 Q3 218 92.0 M $2.91 B
2024 Q2 210 85.3 M $2.99 B
2024 Q1 214 80.7 M $3.54 B
2023 Q4 168 68.1 M $2.42 B
2023 Q3 150 59.7 M $1.61 B
2023 Q2 145 56.6 M $1.33 B
2023 Q1 130 45.6 M $625 M
2022 Q4 123 48.3 M $877 M
2022 Q3 118 45.8 M $684 M
2022 Q2 101 35.9 M $495 M
2022 Q1 108 35.4 M $397 M
2021 Q4 116 34.8 M $823 M
2021 Q3 93 32.9 M $838 M
2021 Q2 86 25.6 M $538 M
2021 Q1 92 23.8 M $605 M
2020 Q4 87 20.3 M $285 M
2020 Q3 69 18.9 M $237 M
2020 Q2 65 18.5 M $262 M
2020 Q1 30 10.9 M $45.0 M
2019 Q4 30 11.2 M $83.6 M
2019 Q3 25 5.57 M $49.5 M
2019 Q2 25 5.65 M $56.3 M